Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Signaturefd LLC

Signaturefd LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.0% in the third quarter, HoldingsChannel reports. The fund owned 2,365 shares of the biopharmaceutical company’s stock after purchasing an additional 23 shares during the period. Signaturefd LLC’s holdings in Regeneron Pharmaceuticals were worth $2,486,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of the stock. West Paces Advisors Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares in the last quarter. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $26,000. Sachetta LLC boosted its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $28,000. Finally, Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research analyst reports. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,108.86.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $962.34 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The business has a fifty day moving average of $1,102.60 and a two-hundred day moving average of $1,041.37. The stock has a market cap of $106.09 billion, a price-to-earnings ratio of 25.49, a price-to-earnings-growth ratio of 3.40 and a beta of 0.12. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the prior year, the company posted $8.79 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.6 earnings per share for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.